Drug firm Cadila Healthcare today reported 31.03 per cent dip in consolidated net profit to Rs 102.91 crore for its third quarter ended December 31, mainly on account of increase in cost of materials consumed.

The group had posted net profit of Rs 149.21 crore after taxes, minority interest and share of profits/loss of the associates, in the same quarter of last fiscal, Cadila Healthcare said in a filing to the BSE.

Consolidated net sales however rose to Rs 1,594.20 crore in Q3, FY’12, from Rs 1,373.64 crore in the year-ago period.

The cost of materials consumed rose to Rs 398.45 crore for the third quarter ended December 31, 2012 as against Rs 249.01 crore for quarter ended December 31, 2011, Cadila Healthcare said.

The company’s scrip closed at Rs 791.35 on the BSE, down 3.02 per cent from the previous close.

(This article was published on February 8, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.